We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice.
- Authors
Zhang, Anqi; Nakano, Daisuke; Kittikulsuth, Wararat; Yamashita, Yuka; Nishiyama, Akira
- Abstract
Proximal tubules (PTs) take up most of the glucose in the glomerular filtrate and return it to peritubular capillary blood. Sodium-glucose cotransporter 2 (SGLT2) at the apical membrane takes up glucose into the cell. Glucose then flows across the cells and is transported to the interstitium via glucose transporter 2 (GLUT2) at the basolateral membrane. However, glucose transport under SGLT2 inhibition remains poorly understood. In this study, we evaluated the dynamics of a fluorescent glucose analog, 2-NBDG, in the PTs of live mice treated with or without the SGLT2 inhibitor, luseogliflozin. We employed real-time multiphoton microscopy, in which insulin enhanced 2-NBDG uptake in skeletal muscle. Influx and efflux of 2-NBDG in PT cells were compared under hypo-, normo-, and hyperglycemic conditions. Luseogliflozin did not exert significant effects on glucose influx parameters under any level of blood glucose. Our results suggest that blood glucose level per se does not alter glucose influx or efflux kinetics in PTs. In conclusion, neither SGLT2 inhibition nor blood glucose level affect glucose uptake kinetics in PTs. The former was because of glucose influx through basolateral GLUT2, which is an established bidirectional transporter.
- Subjects
KIDNEY tubules; SODIUM-glucose cotransporter 2 inhibitors; GLUCOSE; BLOOD sugar; GLUCOSE transporters; SKELETAL muscle
- Publication
International Journal of Molecular Sciences, 2021, Vol 22, Issue 15, p8169
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms22158169